Skip to main content
Top
Published in: Gastric Cancer 2/2020

01-03-2020 | Laparoscopy | Original Article

Conversion therapy for peritoneal lavage cytology-positive type 4 and large type 3 gastric cancer patients selected as candidates for R0 resection by diagnostic staging laparoscopy

Authors: Itaru Yasufuku, Souya Nunobe, Satoshi Ida, Koshi Kumagai, Manabu Ohashi, Naoki Hiki, Takeshi Sano

Published in: Gastric Cancer | Issue 2/2020

Login to get access

Abstract

Background

The long-term outcomes of type 4 and large type 3 gastric cancer patients with positive peritoneal lavage cytology (CY1) remain unsatisfying. We evaluated our treatment strategy of conversion therapy for CY1 patients without peritoneal dissemination (P0).

Methods

Diagnostic staging laparoscopy (DSL) was performed before treatment. Chemotherapy was applied for DSL-diagnosed P0CY1. The re-evaluation of peritoneal metastasis by staging laparoscopy (re-SL) was performed when a response to chemotherapy was identified by gastroscopy and/or CT. Gastrectomy with radical lymphadenectomy was applied as conversion therapy when peritoneal lavage cytology-negative (CY0) and P0 were diagnosed with re-SL, with the aim of achieving R0 resection. Chemotherapy was continued as palliative treatment in patients for whom re-SL was not applicable or when re-SL did not confirm P0CY0. The long-term outcomes were retrospectively evaluated.

Results

Between 2009 and 2015, 214 patients with type 4 and large type 3 gastric cancer underwent DSL in the Cancer Institute Hospital. Thirty-nine patients were initially diagnosed with P0CY1. Seven patients received palliative gastrectomy first due to outlet obstruction or other reasons. Thirty-two patients received chemotherapy first. Among them, 13 patients underwent gastrectomy as conversion therapy and 19 were treated with palliative chemotherapy. The 3-year survival rate of patients who underwent conversion therapy, palliative chemotherapy and palliative gastrectomy was 76.9% [95% confidence interval (CI) 47.8–92.4%], 10.5% (95% CI 1.9–42.3%), and 0%, respectively.

Conclusion

Conversion therapy might be a promising treatment for P0CY1 type 4 and large type 3 gastric cancer patients. Re-SL was useful for selecting candidates for R0 resection.
Literature
1.
go back to reference An JY, Kang TH, Choi MG, Noh JH, Sohn TS, Kim S. Borrmann type IV: an independent prognostic factor for survival in gastric cancer. J Gastrointest Surg. 2008;12:1364–9.CrossRef An JY, Kang TH, Choi MG, Noh JH, Sohn TS, Kim S. Borrmann type IV: an independent prognostic factor for survival in gastric cancer. J Gastrointest Surg. 2008;12:1364–9.CrossRef
2.
go back to reference Li C, Oh SJ, Kim S, Hyung WJ, Yan M, Zhu ZG, et al. Macroscopic Borrmann type as a simple prognostic indicator in patients with advanced gastric cancer. Oncology. 2009;77:197–204.CrossRef Li C, Oh SJ, Kim S, Hyung WJ, Yan M, Zhu ZG, et al. Macroscopic Borrmann type as a simple prognostic indicator in patients with advanced gastric cancer. Oncology. 2009;77:197–204.CrossRef
3.
go back to reference Sasako M, Maruyama K, Kinoshita T, et al. E. Neoadjuvant chemotherapy for gastric cancer: indication and trial setting (in Japanese). Shokakigeka. 1992;15:159–67. Sasako M, Maruyama K, Kinoshita T, et al. E. Neoadjuvant chemotherapy for gastric cancer: indication and trial setting (in Japanese). Shokakigeka. 1992;15:159–67.
4.
go back to reference Miki Y, Tokunaga M, Tanizawa Y, Bando E, Kawamura T, Terashima M. Staging laparoscopy for patients with cM0, type 4, and large type 3 gastric cancer. World J Surg. 2015;39:2742–7.CrossRef Miki Y, Tokunaga M, Tanizawa Y, Bando E, Kawamura T, Terashima M. Staging laparoscopy for patients with cM0, type 4, and large type 3 gastric cancer. World J Surg. 2015;39:2742–7.CrossRef
5.
go back to reference Edge SBBD, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC cancer staging manual. 7th ed. Berlin: Springer; 2009. Edge SBBD, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC cancer staging manual. 7th ed. Berlin: Springer; 2009.
6.
go back to reference Sobin LGM, Wittekind C. TNM classification of malignant tumours. 7th ed. Wiley-Blackwell: Hoboken; 2009. Sobin LGM, Wittekind C. TNM classification of malignant tumours. 7th ed. Wiley-Blackwell: Hoboken; 2009.
7.
go back to reference Japanese classification of gastric carcinoma: 3rd English edition. Gastr Cancer. 2011;14:101–12. Japanese classification of gastric carcinoma: 3rd English edition. Gastr Cancer. 2011;14:101–12.
8.
go back to reference Miyashiro I, Takachi K, Doki Y, Ishikawa O, Ohigashi H, Murata K, et al. When is curative gastrectomy justified for gastric cancer with positive peritoneal lavage cytology but negative macroscopic peritoneal implant? World J Surg. 2005;29:1131–4.CrossRef Miyashiro I, Takachi K, Doki Y, Ishikawa O, Ohigashi H, Murata K, et al. When is curative gastrectomy justified for gastric cancer with positive peritoneal lavage cytology but negative macroscopic peritoneal implant? World J Surg. 2005;29:1131–4.CrossRef
9.
go back to reference Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastr Cancer. 2011;14:113–23. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastr Cancer. 2011;14:113–23.
10.
go back to reference PATE Board. Gastric cancer treatment (PDQ®) health rofessional version. National Cancer Institute: Bethesda; 2018. PATE Board. Gastric cancer treatment (PDQ®) health rofessional version. National Cancer Institute: Bethesda; 2018.
11.
go back to reference Okabe H, Ueda S, Obama K, Hosogi H, Sakai Y. Induction chemotherapy with S-1 plus cisplatin followed by surgery for treatment of gastric cancer with peritoneal dissemination. Ann Surg Oncol. 2009;16:3227–36.CrossRef Okabe H, Ueda S, Obama K, Hosogi H, Sakai Y. Induction chemotherapy with S-1 plus cisplatin followed by surgery for treatment of gastric cancer with peritoneal dissemination. Ann Surg Oncol. 2009;16:3227–36.CrossRef
12.
go back to reference Kodera Y, Ito S, Mochizuki Y, Ohashi N, Tanaka C, Kobayashi D, et al. Long-term follow up of patients who were positive for peritoneal lavage cytology: final report from the CCOG0301 study. Gastr Cancer. 2012;15:335–7.CrossRef Kodera Y, Ito S, Mochizuki Y, Ohashi N, Tanaka C, Kobayashi D, et al. Long-term follow up of patients who were positive for peritoneal lavage cytology: final report from the CCOG0301 study. Gastr Cancer. 2012;15:335–7.CrossRef
13.
go back to reference Aizawa M, Nashimoto A, Yabusaki H, Nakagawa S, Matsuki A, Homma K, et al. The clinical significance of potentially curative resection for gastric cancer following the clearance of free cancer cells in the peritoneal cavity by induction chemotherapy. Surg Today. 2015;45:611–7.CrossRef Aizawa M, Nashimoto A, Yabusaki H, Nakagawa S, Matsuki A, Homma K, et al. The clinical significance of potentially curative resection for gastric cancer following the clearance of free cancer cells in the peritoneal cavity by induction chemotherapy. Surg Today. 2015;45:611–7.CrossRef
14.
go back to reference Yoshida K, Yamaguchi K, Okumura N, Tanahashi T, Kodera Y. Is conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classification. Gastr Cancer. 2016;19:329–38.CrossRef Yoshida K, Yamaguchi K, Okumura N, Tanahashi T, Kodera Y. Is conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classification. Gastr Cancer. 2016;19:329–38.CrossRef
15.
go back to reference Terashima M. Conversion therapy for gastric cancer: who can make conversion as successful as Goromaru? Gastr Cancer. 2016;19:685–6.CrossRef Terashima M. Conversion therapy for gastric cancer: who can make conversion as successful as Goromaru? Gastr Cancer. 2016;19:685–6.CrossRef
16.
go back to reference Leake PA, Cardoso R, Seevaratnam R, Lourenco L, Helyer L, Mahar A, et al. A systematic review of the accuracy and indications for diagnostic laparoscopy prior to curative-intent resection of gastric cancer. Gastr Cancer. 2012;15(Suppl 1):S38–47.CrossRef Leake PA, Cardoso R, Seevaratnam R, Lourenco L, Helyer L, Mahar A, et al. A systematic review of the accuracy and indications for diagnostic laparoscopy prior to curative-intent resection of gastric cancer. Gastr Cancer. 2012;15(Suppl 1):S38–47.CrossRef
17.
go back to reference Tsuburaya A, Mizusawa J, Tanaka Y, Fukushima N, Nashimoto A, Sasako M. Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis. Br J Surg. 2014;101:653–60.CrossRef Tsuburaya A, Mizusawa J, Tanaka Y, Fukushima N, Nashimoto A, Sasako M. Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis. Br J Surg. 2014;101:653–60.CrossRef
18.
go back to reference Kodera Y, Ito S, Mochizuki Y, Kondo K, Koshikawa K, Suzuki N, et al. A phase II study of radical surgery followed by postoperative chemotherapy with S-1 for gastric carcinoma with free cancer cells in the peritoneal cavity (CCOG0301 study). Eur J Surg Oncol. 2009;35:1158–63.CrossRef Kodera Y, Ito S, Mochizuki Y, Kondo K, Koshikawa K, Suzuki N, et al. A phase II study of radical surgery followed by postoperative chemotherapy with S-1 for gastric carcinoma with free cancer cells in the peritoneal cavity (CCOG0301 study). Eur J Surg Oncol. 2009;35:1158–63.CrossRef
19.
go back to reference Irino T, Sano T, Hiki N, Ohashi M, Nunobe S, Kumagai K, et al. Diagnostic staging laparoscopy in gastric cancer: a prospective cohort at a cancer institute in Japan. Surg Endosc. 2018;32:268–75.CrossRef Irino T, Sano T, Hiki N, Ohashi M, Nunobe S, Kumagai K, et al. Diagnostic staging laparoscopy in gastric cancer: a prospective cohort at a cancer institute in Japan. Surg Endosc. 2018;32:268–75.CrossRef
20.
go back to reference Blank S, Lordick F, Bader F, Burian M, Dobritz M, Grenacher L, et al. Post-therapeutic response evaluation by a combination of endoscopy and CT scan in esophagogastric adenocarcinoma after chemotherapy: better than its reputation. Gastr Cancer. 2015;18:314–25.CrossRef Blank S, Lordick F, Bader F, Burian M, Dobritz M, Grenacher L, et al. Post-therapeutic response evaluation by a combination of endoscopy and CT scan in esophagogastric adenocarcinoma after chemotherapy: better than its reputation. Gastr Cancer. 2015;18:314–25.CrossRef
21.
go back to reference Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.CrossRef Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.CrossRef
Metadata
Title
Conversion therapy for peritoneal lavage cytology-positive type 4 and large type 3 gastric cancer patients selected as candidates for R0 resection by diagnostic staging laparoscopy
Authors
Itaru Yasufuku
Souya Nunobe
Satoshi Ida
Koshi Kumagai
Manabu Ohashi
Naoki Hiki
Takeshi Sano
Publication date
01-03-2020
Publisher
Springer Singapore
Published in
Gastric Cancer / Issue 2/2020
Print ISSN: 1436-3291
Electronic ISSN: 1436-3305
DOI
https://doi.org/10.1007/s10120-019-00994-0

Other articles of this Issue 2/2020

Gastric Cancer 2/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.